Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyBlue Cross Blue Shield - Kansas Prior Auth List | …
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - KansasPolicy N/A

    Prior Authorization list for non-formulary and formulary drugs

    Customize your policy alerts

    Sign up for all blue cross blue shield - kansas policy alerts

    Know when blue cross blue shield - kansas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists medications (by drug/group) that may require prior authorization (PA) and indicates where PA forms should be submitted; it applies to Blue Cross Blue Shield - Kansas members and providers seeking PA information. Coverage/PA requirements may vary by plan and should be verified for individual members.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBlue Cross Blue Shield - Kansas
    PolicyPrior Authorization list for non-formulary and formulary drugs
    Policy CodePolicy N/A
    Change TypeNo material changes noted
    Effective DateN/A
    Next Review DateN/A
    Key ActionVerify member coverage and PA requirements by calling 800-432-3990 or sending an electronic inquiry through your local Blue Plan.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+document chunks
    MultiplePA submission channels
    90+drug entries listed

    Prior Authorization Coverage Criteria and Drug List

    General coverage stance

    The following describes the plan-level stance for prior authorization (PA) in this listing.

    Listed medications and medication groups may require prior authorization (PA) before coverage is approved.
    PA requirements are plan-specific and the list does not apply to all group health plans or all members.
    To verify whether PA is required for a particular member, call 800-432-3990 or send an electronic inquiry through your established connection with your local Blue Plan.
    This list may not be all inclusive; verify coverage and PA requirements for individual members.

    Enumerated PA drug list and submission locations

    The drugs and drug groups below require prior authorization; the designated submission location for PA requests is shown with each entry.

    Examples (not exhaustive)

    • Ilaris — Where to submit PA form = Prime Therapeutics/Gateway PA.
    • Ilumya — Where to submit PA form = Prime Therapeutics/Gateway PA.
    • Imfinzi — Where to submit PA form = Prime Therapeutics/Gateway PA.
    • Infliximab (Remicade, Renflexis) — Where to submit PA form = Prime Therapeutics/Gateway PA.
    • Injectafer — Where to submit PA form = Prime Therapeutics/Gateway PA.
    • Insulin Combination Agents (Soliqua, Xultophy) — Where to submit PA form = Prime Therapeutics/Cover My Meds.

    List of drugs requiring prior authorization (administrative list)

    Additional listed drugs require prior authorization; each entry in the administrative list specifies the submission portal for PA requests.

    Selected administrative entries

    • Spevigo IV/SQ — Where to submit PA form = Prime Therapeutics/Gateway PA.
    • Spinraza — Where to submit PA form = Prime Therapeutics/Gateway PA.
    • Statin products (Altoprev, Zypitamag, etc.) — Where to submit PA form = Prime Therapeutics/Cover My Meds.
    • Strensiq — Where to submit PA form = Prime Therapeutics/Cover My Meds.
    • Substrate Reduction Therapy (Cerdelga, Opfolda, Zavesca) — Where to submit PA form = Prime Therapeutics/Cover My Meds.

    Codes and Device/Drug Group Listings

    Device/drug groups listed (examples)mixed
    Continuous Glucose Monitoring (PA required under pharmacy benefit) — Dexcom G6 CGM System; Dexcom G7 CGM System; Eversense; Eversense 365; Eversense e3; Freestyle Libre; Freestyle Libre 2; Freestyle Libre 3; Guardian 4; Medtronic Instinct sensors; Medtronic MiniMed Guardian Connect System; Simplera Sync.
    Corticotropin — Purified Cotrphin Gel.
    Corticotropin-ACTH — Acthar Gel; Cortrophin Gel.
    Cosentyx — Cosentyx.
    Crenessity — Crenessity.
    Crysvita — Crysvita.
    Ctexli — Ctexli.
    Cyramza — Cyramza.
    Self-administered oncology agentsmixedCovered
    Self-Administered Oncology Agents — examples include abiraterone, Afinitor, Afinitor Disperz, and an extensive list of oral oncology agents requiring prior authorization; PA submission via Prime Therapeutics/Cover My Meds or Prime Therapeutics/Gateway PA as specified.
    No billing or procedure codes listed in this sectionmixed
    No codes listed

    Provider Submission Instructions and Actions

    Prior Authorization

    How to verify PA requirements

    Verify prior authorization (PA) requirements before prescribing or dispensing. To confirm coverage, benefits, or whether a PA is required for a specific member, call Blue Cross Blue Shield of Kansas Provider Services: In Topeka: 785-291-7000; In Kansas: 800-432-0216; or send an electronic inquiry through your established connection with your local Blue Plan. Electronic PA submissions are routed either to Prime Therapeutics (Gateway PA) or via CoverMyMeds depending on the medication — see drug-specific entries below for the correct submission pathway.

    • Call to verify coverage and PA requirements: In Topeka: 785-291-7000; In Kansas: 800-432-0216
    • Electronic inquiries: send via your established connection with your local Blue Plan
    • PA submission destinations: Prime Therapeutics (Gateway PA) or CoverMyMeds — check drug-specific routing
    Prior Authorization

    Drug-specific PA requirements and submission location

    Certain drugs and product classes have specific PA requirements and designated submission destinations. Submit PA forms to Prime Therapeutics (Gateway PA) or to CoverMyMeds as noted. Some products are exceptions and must be submitted directly to BCBSKS — these are called out in the BCBSKS exceptions entry.

    Definitions and Submission Pathway Glossary

    Prior Authorization (PA) — definition
    DefinitionPrior Authorization (PA) is a plan-specific review process that may be required for certain medications before coverage is approved.
    ApplicabilityPA may be required for listed medications but not for all plans; verify coverage for each member.
    How to verifyTo verify coverage, benefits or PA requirements for a particular member call 800-432-3990 or send an electronic inquiry through your established connection with your local Blue Plan.
    ScopeThis list may not be all-inclusive and applies to Blue Cross Blue Shield - Kansas members and providers seeking PA information.
    PA submission pathways
    Primary vendor/pathwayPrime Therapeutics — Gateway PA is the primary submission pathway for many listed medications.
    Policy Summary
    PayerBlue Cross Blue Shield - Kansas
    PolicyPrior Authorization list for non-formulary and formulary drugs
    Policy CodePolicy N/A
    Change TypeNo material changes noted
    Effective DateN/A
    Next Review DateN/A
    Key ActionVerify member coverage and PA requirements by calling 800-432-3990 or sending an electronic inquiry through your local Blue Plan.
    SourceLink
    On This Page
    Prior Authorization Coverage Criteria and Drug ListCodes and Device/Drug Group ListingsProvider Submission Instructions and ActionsDefinitions and Submission Pathway Glossary
    Insulin Pump (Omnipod products, V-Go) — Where to submit PA form = Prime Therapeutics/Cover My Meds.
  1. Interleukin agents (e.g., Dupixent, Arcalyst) — Where to submit PA form = Prime Therapeutics/Cover My Meds.
  2. IVIG/SCIG products (Alyglo, Asceniv, Cutaquig, Gammaplex, etc.) — Where to submit PA form = Prime Therapeutics/Gateway PA.
  3. Long-acting granulocyte colony stimulating factors (Fulphila, Nyvepria, etc.) — Where to submit PA form = Prime Therapeutics/Gateway PA.
  4. Long-acting insulin (insulin degludec, insulin glargine, Rezvoglar) — Where to submit PA form = Prime Therapeutics/Cover My Meds.
  5. Self-Administered Oncology Agents (extensive oral agents list) — Where to submit PA form = Prime Therapeutics/Cover My Meds.
  6. Spevigo (IV/SQ), Spinraza, Strensiq, Substrate Reduction Therapy agents — Where to submit PA form = Prime Therapeutics (Gateway PA or Cover My Meds) as specified.
  7. Many specialty oncology and biologic agents (Sustol, Susvimo, Synagis, Tecartus, Tecelra, etc.) — Where to submit PA form = Prime Therapeutics/Gateway PA or Cover My Meds per listing.
  8. Some specific gene, cell, or specialty products (e.g., Itvisma, Lenmeldy, Luxturna, Lyfgenia, Rethymic, Roctavian, Vyjuvek, Zevaskyn, Zolgensma, Zynteglo) have PA forms submitted directly to BCBSKS as indicated in the listing.
    Sucraid, Sunosi — Where to submit PA form = Prime Therapeutics/Cover My Meds.
  9. Sustol, Susvimo, Syfovre, Synagis, Takhzyro, Talvey, Tavneos, Tecartus, Tecelra — Where to submit PA form = Prime Therapeutics/Gateway PA or Cover My Meds per listing.
  10. Tecentriq (IV and Hybreza), Tecvayli, Tepezza, Tezspire, Tivdak, Tocilizumab — Where to submit PA form = Prime Therapeutics/Gateway PA.
  11. Topical Doxepin, Topiramate ER, Trastuzumab IV, Tremfya, Trodelvy, Ultomiris — Where to submit PA form = Prime Therapeutics (Gateway PA or Cover My Meds) as specified.
  12. Uplizna, Ustekinumab, Vabysmo, VPRIV, Vyepti, Vectibix, Vimizim, Voydeya, Vyvgart — Where to submit PA form = Prime Therapeutics (Gateway PA or Cover My Meds) or BCBSKS when specified.
  13. Many additional agents listed in chunks 36–45 require PA and identify the specific submission portal (Prime Therapeutics/Gateway PA; Prime Therapeutics/Cover My Meds; or BCBSKS) alongside each drug name.
    • Examples of drug-specific PA routing: Ilaris, Ilumya, Imfinzi, Influximab (Remicade, Renflexis), Injectafer, Imjudo — submit to Prime Therapeutics/Gateway PA
    • Insulin combination agents (Soliqua, Xultophy) and insulin pumps (Omnipod family, V-Go) — submit to Prime Therapeutics/Cover My Meds
    • Interleukin agents (e.g., Arcalyst, Dupixent, Adbry, Nemluvio) — submit to Prime Therapeutics/Cover My Meds
    Prior Authorization

    PA submission pathways for ambulatory agents

    Ambulatory agents and device-related products follow designated PA submission pathways. Use the stated pathway for timely processing.

    • Insulin combination agents (Soliqua, Xultophy): Prime Therapeutics/Cover My Meds
    • Insulin pumps (Omnipod, Omnipod DASH, Omnipod GO, Omnipod 5 G6, V-Go): Prime Therapeutics/Cover My Meds
    • Interstitial lung disease agents (Esbriet, Ofev, pirfenidone): Prime Therapeutics/Cover My Meds
    Prior Authorization

    BCBSKS submission exceptions

    Some products are exceptions and require PA forms to be submitted directly to Blue Cross Blue Shield of Kansas (BCBSKS) rather than to Prime Therapeutics or CoverMyMeds. Verify submission destination prior to sending the PA.

    • BCBSKS submission examples: Itvisma, Kebilidi, Luxturna, Lyfgenia, Vyjuvek
    Prior Authorization

    Specialty biologics and supportive agents PA

    Specialty biologics and supportive agents (including long-acting G-CSF, long-acting insulins, SCIG/IVIG, enzyme replacement therapies, and similar specialty biologics) generally require PA and have specific routing instructions. Check the drug entry for the correct submission destination.

    • Long-acting granulocyte colony stimulating factors (e.g., Fulphila, Nyvepria, Rolvedon, Udenyca, Ziextenzo): Prime Therapeutics/Gateway PA
    • Long-acting insulin (insulin degludec, Lantus, Rezvoglar): Prime Therapeutics/Cover My Meds
    • SCIG/IVIG and enzyme replacement therapies (e.g., Lumizyme, Aldurazyme): Prime Therapeutics/Gateway PA
    Prior Authorization

    PA submission locations for listed drugs (examples)

    The list below gives additional examples of drugs and their PA submission locations. Always verify the submission destination for the specific product and member plan prior to submission.

    • Spevigo IV/SQ, Spinraza, Sustol, Susvimo, Syfovre, Synagis, Tecartus, Tecelra, Vyepti, VPRIV — submit to Prime Therapeutics/Gateway PA
    • Statin products listed (Altoprev, Atorvaliq, Zypitamag, etc.), Strensiq, substrate reduction therapies (Cerdelga, Opfolda, Zavesca) — submit to Prime Therapeutics/Cover My Meds
    • Sunosi, Sucraid, Wakix, weight loss agents listed — submit to Prime Therapeutics/Cover My Meds
    Prior Authorization

    PA submission locations for additional specialty agents

    Additional oncology, gene therapy, and high-cost specialty agents have specified submission routes; a subset is required to be submitted directly to BCBSKS.

    • Oncology and specialty biologics submitted to Prime Therapeutics/Gateway PA include: Keytruda IV/SQ, Kimmtrak, Krystexxa, Kymriah, Tavneos, Talvey, Takhzyro
    • Gene and cell therapies or other BCBSKS-direct submissions include: Luxturna, Lyfgenia, Vyjuvek, and other BCBSKS-designated products
    • Refer to the individual drug entry for the required submission pathway (Prime Therapeutics Gateway PA, CoverMyMeds, or BCBSKS)
    Prior Authorization

    BCBSKS-specific PA submission

    BCBSKS-specific submission destination — for certain named products, the PA form must be submitted directly to Blue Cross Blue Shield of Kansas rather than to Prime Therapeutics or CoverMyMeds. Confirm these exceptions for the member's plan before submitting.

    • Products requiring submission to BCBSKS: Itvisma, Kebilidi, Luxturna, Lyfgenia, Vyjuvek, and other BCBSKS-designated therapies
    Alternate vendorPrime Therapeutics — Cover My Meds is used for selected outpatient and self‑administered drugs (example: Acute Migraine Agents, Multiple Sclerosis Agents, Statins).
    BCBSKS direct submissionCertain products are submitted directly to BCBSKS as specified in individual drug entries.
    Verification noteSubmission pathway is drug-specific; check the listed destination for each medication before submitting PA forms.
    Self‑Administered Oncology Agents — note
    DefinitionSelf‑Administered Oncology Agents are oral oncology medications that require prior authorization and are routed via the specified submission pathway (typically Prime Therapeutics/Cover My Meds).
    Example scopeThe document lists numerous oral oncology agents (see Self‑Administered Oncology Agents entries) that require PA.
    Submission routingRoute PA requests for these agents through the vendor indicated on the drug entry (often Prime Therapeutics/Cover My Meds).
    PA submission destination — where to send forms
    Submit to Prime Therapeutics/Gateway PAMany IV, specialty and high‑cost medications list Prime Therapeutics/Gateway PA as the PA submission destination (e.g., Abecma, Ilaris, Imfinzi, Spevigo, Spinraza).
    Submit via Prime Therapeutics/Cover My MedsSelected outpatient, oral and self‑administered drugs route PA forms through Prime Therapeutics/Cover My Meds (e.g., Acute Migraine Agents, Multiple Sclerosis Agents, Statin products).
    Submit to BCBSKSCertain products are designated for direct submission to BCBSKS as specified on the individual drug entry; verify per drug listing.
    Check drug entryThe correct destination is listed alongside each medication — confirm the specified portal/vendor before submitting the PA form.